Such a therapeutic effect is seemingly attributed to its inhibition of heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) binding, thereby facilitating the inclusion of exon 7 in the SMN2 transcript and leading to the production of the full-length SMN2 protein, which is essential for combating SMA. Here, SMN2 is linked to proximal spinal muscular atrophy.